Please note that all agenda timings are Eastern Time. For PDT time and full session descriptions download the Full Event Guide here

8:30 am Virtual Coffee & Registration

8:50 am Chair’s Opening Remarks

Repurposing and Repositioning For Infectious Diseases Including Covid-19

9:00 am Panel Discussion – Repurposing Prominence During Covid-19


Drug repurposing has shone during the pandemic, but will the lessons learned translate into a more
organized response for future pandemics?

9:45 am Case Study – The Powerful Impact of Artificial Intelligence on SARS-CoV-2 Drug Repurposing Efforts


• Why AI and machine learning models are necessary to repurpose drugs in response to Covid-19
• Leveraging AI technology is providing promising repurposing results
• Drug repurposing has an exciting future, with further successful AI models for repurposing to come

10:15 am Virtual Speed Networking

10:45 am Morning Break

11:15 am Case Study – The Role Repurposing Can Play in Covid-19 & Other Infectious Diseases


• Learning from repurposing in other infectious disease areas
• Exploring the advantages and limitations of drug repurposing
• Overview of different AI approaches in repurposing for Covid-19
• Steps to gauge if a potential repurposing project is worth actioning – balancing development and commercial risk

11:45 am Case Study – Computational Drug Repurposing with the Addition of Real World Validation using Molecular & Observational Data

  • Danica Xiao Director, Machine Learning Analytics Center of Excellence , IQVIA


• AI driven drug repurposing has huge potential to positively disrupt
R&D processes we want to ensure recommendations and findings have
validation in the real world
• Based on our existing drug discovery solutions, we explore external
validation for repurposed drugs using longitudinal medical claims data

Impact of AI-Driven Drug Repurposing in Oncology, Rare & Infectious Disease

12:15 pm Pre-Workshop Interim & Lunch

12:45pm Deep Dive into AI- Lunchtime Workshop:

  • Giovanni Bocci Postdoc Fellow, University of New Mexico
  • Tudor Oprea Professor - Medicine & Chief of Translational Informatics Division & Internal Medicine, University of New Mexico


Artificial Intelligence, Drug Repurposing & Covid-19
From the onset of Covid-19, organizations from many different backgrounds have been quick to transition resources and apply their artificial intelligence expertise across the full spectrum of drug discovery and development. It is clear artificial intelligence and machine learning can play a large role in overcoming the crisis by enabling the medical community, policy makers, and general public with the right tools to manage every stage of the crisis; from detection, prevention and response, to recovery and accelerating research and treatment efforts.

This workshop details drug repositioning efforts in finding candidates with the optimal profile for clinical success.

Topics of Discussion Include:

• Discussing ML and its use to identify biological targets for therapeutic intervention in heterogeneous disease and find suitable drug candidates that bind those targets
• Machine learning models for estimating small molecule activity from molecular structure, for a range of SARS-CoV-2 related assays

2:00 pm Case Study – Using Machine Learning & Artificial Intelligence to Discover Repurposed Rare & Orphan Disease Drug Candidates

  • Steve Smith Principal Computational Biology Data Scientist, Teva Pharmaceuticals


• Why drug repurposing in rare and orphan disease research can benefit greatly from AI technologies
• Example of how AI has been used to enhance repurposing of therapeutics for rare and orphan diseases
• Challenges and improvements to be successful in AL-directed drug repurposing

2:30 pm Reducing Interface Bottlenecks for AI-Powered Drug Discovery with Virtual Reality


  • Compute more intuitively by integrating with cloud resources
  • Collaborate with colleagues around the world virtually
  • Accelerate new discoveries with better data visualization

3:00 pm Case Study – Advancing Treatments in Oncology Through Repurposing Technology


• Improving the efficiency of oncology drug development through generic drug repurposing
• Leveraging AI to accelerate the identification of promising cancer treatments
• Applying evidence synthesis technology to help cancer patients who contract COVID-19

Getting Started With AI-Powered Drug Repurposing Projects

3:30 pm Panel Discussion – Overcoming the Challenges Faced When Converting Actionable Hypotheses into Meaningful Experimentation Work


• Discussing barrier to entry in starting a repurposing project: How much domain expertise is required to action a viable repurposing opportunity? Once predictions have been made, what do you do then?

4:00 pm Afternoon Networking Break

4:30 pm Case Study – Harnessing AI Tools in Drug Repurposing to Discover New Indications & Extend a Drugs Usage

  • David Hayes Director, Emergent Innovations, AstraZeneca


• Getting the basics right in setting up your methodology to discover new indications
• Critically examining AI techniques in drug repurposing
• Remaining mindful of the challenges that lie ahead; data quality, data heterogeneity, data sharing and access among companies, and interpretability of models

Patient Perspectives & Clinical Trials

5:00 pm Case Study – Strengthening POC Repurposing Trials Using AI


• Sharing examples when AI information has helped develop the POC clinical trial
• How this impacts the clinical trial review process and/or strengthens the likelihood of success of a POC trial

5:30 pm Fireside Chat – Patient Perspectives on Repurposing Discoveries


Addressing major considerations for the academics, healthcare institutions and companies in addressing patient needs and priorities

6:00 pm Chair’s Closing Remarks and End of Day 1